ArticleRevista panamericana de salud publica = Pan American journal of public health2024
[Successes and challenges in achieving and sustaining the elimination of measles, rubella, and congenital rubella syndrome in the Americas, 2013-2023Conquistas e desafios para alcançar e manter a eliminação do sarampo, da rubéola e da síndrome da rubéola congênita na Região das Américas, 2013-2023].
Article in Revista panamericana de salud publica = Pan American journal of public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Congenital Rubella Syndrome in the Post-Elimination Era: Why Vigilance Remains Essential.Journal of clinical medicine · 2025Review
- [Risk factors and control measures in measles outbreaks in countries of the Region of the Americas, 2017-2023Fatores de risco e medidas de controle em surtos de sarampo em países da Região das Américas, 2017-2023].Revista panamericana de salud publica = Pan American journal of public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objetivo: To document the historical facts and the challenges faced in the Region of the Americas in achieving and sustaining measles, rubella, and congenital rubella syndrome (CRS) elimination between 2013 and 2023. Method: Special report with a narrative description of the main achievements, challenges, and lessons learned during the period, and an analysis of vaccination coverage, surveillance indicators, and measles outbreaks using data from the Pan American Health Organization and the United Nations Children's Fund, among others. Results: Between 2003 and 2016, regional vaccination coverage with the first dose of the measles, rubella, and mumps vaccine was between 92% and 94%; after 2017 there was a marked decline due to lower coverage levels in the most populous countries. The regional reporting rate of suspected cases remained at the expected level, with differences in each subregion. Between 2017 and 2023, measles outbreaks tested the strengths and weaknesses in the quality of each country's response. Starting in 2020, the COVID-19 pandemic had a negative impact on both vaccination coverage and the quality of epidemiological surveillance. Conclusions: The elimination of measles in 2016 and rubella in 2015 were major achievements in the Region of the Americas. Between 2017 and 2020, the main challenge was to address measles outbreaks that caused the re-establishment of endemic transmission in two countries. Between 2020 and 2023, the main challenge was to tackle the negative impact of the COVID-19 pandemic on declining vaccination coverage and surveillance indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.